Eubiosis and dysbiosis: The two sides of the microbiota

New Microbiologica

Volumn 39, Issue 1, 2016, Pages 1-12

  Iebba, Valerio ^a   Totino, Valentina ^a   Gagliardi, Antonella ^a   Santangelo, Floriana ^a   Cacciotti, Fatima ^a   Trancassini, Maria ^a   Mancini, Carlo ^a   Cicerone, Clelia ^a   Corazziari, Enrico ^a   Pantanella, Fabrizio ^a   Schippa, Serena ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dysbiosis; Eubiosis; Intestinal microbiota

Indexed keywords

DYSBIOSIS; GASTROINTESTINAL TRACT; HUMAN; INTESTINE FLORA; MICROBIOLOGY;

DYSBIOSIS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS;

EID: 84959337606     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Alakomi H.L., Skytt E., Saarela M., Mattila-Sandholm T., Latva-Kala K., Helander I.M. (2000). Lactic Acid Permeabilizes Gram-Negative Bacteria by Disrupting the Outer Membrane. Appl. Environ. Microbiol. 66, 2001-2005.
2. Aleandri M., Conte M.P., Simonetti G., Panella S., Celestino I., Checconi P., et al. (2015). Influenza A virus infection of intestinal epithelial cells enhances the adhesion ability of Crohns disease associated Escherichia coli strains. PLoS One. 10, e0117005.
3. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., et al. (2011). Enterotypes of the human gut microbiome. Nature. 473, 12.
4. Barnich N., Darfeuille-Michaud A. (2007). Adherent-invasive Escherichia coli and Crohns disease. Curr. Opin. Gastroenterol. 23 (1), 16-20.
5. Belkaid Y., Hand T. (2014). Role of the Microbiota in Immunity and inflammation. Cell. 157, 121-141.
6. Bertin J., Nir W.J., Fischer C.M., Tayber O.V., Errada P.R., Grant J.R., Keilty J.J., et al. (1999). Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. J. Biol. Chem. 274, 12955-12958.
7. Blaser M.J. (2006). Hogenicity and symbiosis: human gastric colonization by helicobacter pylori as a model system of amphibiosis. Ending the war metaphor: The changing agenda for unraveling the host-microbe relationship. Workshop summary.
8. Brandt L.J., Aroniadis O.C., Mellow M., Kanatzar A., Kelly C., Park T. (2012). Long-Term Follow-up Study of Fecal Microbiota Transplantation (FMT) for Severe or Complicated Clostridium difficile Infection (CDI). Am. J. Gastroenterol. 107, 1079-1087.
9. Buffie C.G., Pamer E.G. (2013). Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13, 790-801.
10. Cammarota G., Ianiro G., Bibb S., Gasbarrini A. (2014). Fecal microbiota transplantation: A new old kid on the block for the management of gut microbiota-related disease. J. Clin. Gastroenterol. 48, S80-84.
11. Cao Y., Shen J., Ran Z.H. (2014). Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A meta-Analysis and systematic review of the literature. Gastroenterology Research and Practice. 2014, 872725.
12. Cario E. (2002). Toll-like receptors and gastrointestinal diseases: from bench to bedside? Curr. Opin. Gastroenterol. 18, 696-704.
13. Cash H.L., Whitham C.V., Behrendt C.L., Hooper L.V. (2006). Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 313, 1126-1130.
14. Cebra J.J. (1999). Influences of microbiota on intestinal immune system development. Am. J. Clin. Nutr. 69, 1046S-1051S.
15. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. (2010). Clinical practice guidelines for Clostridium difficile infection in adults, update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455.
16. Conte M.P., Schippa S., Zamboni I., Penta M., Chiarini F., Seganti L., et al. (2006). Gut-Associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 55, 1760-1767.
17. Conte M.P., Longhi C., Marazzato M., Conte A.L., Aleandri M., Lepanto M.S., et al. (2014). Adherent-invasive Escherichia coli (AIEC) in pediatric Crohns disease patients: phenotypic and genetic pathogenic features. BMC Res. Notes. 22, 7-748.
18. Crouzet L., Rigottier-Gois L., Serror P. (2015). Potential use of probiotic and commensal bacteria as non-Antibiotic strategies against vancomycin-resistant enterococci. FEMS Microbiol. Lett. 362, fnv012.
19. Darfeuille-Michaud A. (2002). Adherent-invasive Escherichia coli: A putative new E. coli pathotype associated with Crohns disease. Int. J. Med. Microbiol. 292, 185-193.
20. Darfeuille-Michaud A., Boudeau J., Bulois P., Neut C., Glasser A.L., Barnich N., et al. (2004). High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohns disease. Gastroenterology. 127, 412-421.
21. De Palma G., Nadal I., Medina M., Donat E., Ribes-Koninckx C., Calabuig M., Sanz Y. (2010). Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 10, 63.
22. Diaz H.R., Wang S., Anuar F., Qian Y., Bjkholm B., Samuelsson A., et al. (2011). Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. USA. 108, 3047-3052.
23. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., et al. (2005). Diversity of the human intestinal microbial flora. Science. 308, 1635-1638.
24. Duboc H., Rajca S., Rainteau D., Benarous D., Maubert M.A., Quervain E., et al. (2013). Connecting dysbiosis, bile-Acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 62, 531-539.
25. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel dis eases. Proc. Natl. Acad. Sci. USA. 104, 13780-1378.
26. Gallegos-Orozco J.F., Paskvan-Gawryletz C.D., Gurudu S.R., Orenstein R. (2012). Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis. Rev. Gastroenterol. Mex. 77, 40-42.
27. Gill S.R., Pop M., Deboy R.T., Eckburg P.B., Turnbaugh P.J., Samuel B.S., et al. (2006). Metagenomic analysis of the human distal gut microbiome. Science. 312, 1355-1359.
28. Gough E., Shaikh H., Manges A.R. (2011). Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53, 994-1002.
29. Guo B., Harstall C., Louie T., Veldhuyzen van Zanten S., Dieleman L.A. (2012). Systematic review: faecal transplantation for the treatment of Clostridium difficile-Associated disease. Aliment. Pharmacol. Ther. 35, 865-875.
30. Haller D. (2006). Intestinal epithelial cell signalling and host-derived negative regulators under chronic inflammation: To be or not to be activated determines the balance towards commensal bacteria. Neurogastroenterol. Motil. 18, 184-199.
31. Harris M.A., Reddy C.A., Carter G.R. (1976). Anaerobic bacteria from the large intestine of mice. Appl. Environ. Microbiol. 31, 907-912.
32. Hayden M.S., West A.P., Ghosh S. (2006). NF-kappaB and the immune response. Oncogene. 25, 6758-6780.
33. Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., Gordon J.I. (2001). Molecular analysis of commensal host-microbial relationships in the intestine. Science. 291, 881-884.
34. Iebba V., Conte M.P., Lepanto M.S., Di Nardo G., Santangelo F., Aloi M., et al. (2012). Microevolution in fimH gene of mucosa-Associated Escherichia coli strains isolated from pediatric patients with inflammatory bowel disease. Infect. Immun. 80, 1408-1417.
35. Iebba V., Totino V., Santangelo F., Gagliardi A., Ciotoli L., Virga A., et al. (2014). Bdellovibrio bacteriovorus directly attacks Pseudomonas aeruginosa and Staphylococcus aureus Cystic fibrosis isolates. Front. Microbiol. 5, 280.
36. Inohara N., Koseki T., del Peso L., Hu Y., Yee C., Chen S., et al. (1999). Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J. Biol. Chem. 274, 14560-14567.
37. Inohara N., Ogura Y., Fontalba A., Gutierrez O., Pons F., Crespo J., et al. (2003). Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohns disease. J. Biol. Chem. 278, 5509-5512.
38. Jeffery I.B., Claesson M.J., OToole P.W., Shanahan F. (2012). Categorization of the gut microbiota: enterotypes or gradients? Nat. Rev. Microbiol. 10, 591-592.
39. Kamada N., Seo S., Chen G.Y., Nez G. (2013). Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13, 321-335.
40. Kassam Z., Lee C.H., Yuan Y., Hunt R.H. (2013). Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-Analysis. Am. J. Gastroenterol. 108, 500-508.
41. Kawai T., Akira S. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384.
42. Kelly C.P., LaMont J.T. (2008). Clostridium difficilemore difficult than ever. N. Engl. J. Med. 359, 1932-1940.
43. Kida Y., Shimizu T., Kuwano K. (2006). Sodium butyrate up-regulates cathelicidin gene expression via activator protein-1 and histone acetylation at the promoter region in a human lung epithelial cell line, EBC-1. Mol. Immunol. 43, 1972-1981.
44. Korecka A., Arulampalam V. (2012). The gut microbiome: scourge, sentinel or spectator? J. Oral. Microbiol. 4, 9367.
45. Kronman M.P., Zerr D.M., Qin X., Englund J., Cornell C., Sanders J.E. (2014). Intestinal decontamination of multidrug-resistant Klebsiella pneumoniae after recurrent infections in an immunocompromised host. Diagn. Microbiol. Infect. Dis. 80, 87-89.
46. Lavelle E.C., Murphy C., ONeill L.A., Creagh E.M. (2010). The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal. Immunol. 3, 17-28.
47. Lee Y.K., Mazmanian S.K. (2014). Microbial learning lessons: SFB educate the immune system. Immunity. 40, 457-459.
48. Ley R.E., Peterson D.A., Gordon J.I. (2006). Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 124, 837-848.
49. Liin-Le Moal V., Servin A.L. (2006). The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin. Microbiol. Rev. 19, 315-337.
50. Lopez-Siles M., Martinez-Medina M., Busquets D., Sabat-Mir M., Duncan S.H., Flint H.J., et al. (2014). Mucosa-Associated Faecalibacterium prausnitzii and Escherichia colico-Abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. International Journal of Medical Microbiology. 304, 464-475.
51. Macpherson A.J., Uhr T. (2004). Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 303, 1662-1665.
52. Mariat D., Firmesse O., Levenez F., Guimarəes V., Sokol H., Dor J., et al. (2009). The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 9, 123.
53. Martin J., Nichols J.D., McIntyre C.L., Ferraz G., Hines J.E. (2009). Perturbation analysis for patch occupancy dynamics. Ecology. 90, 10-16.
54. Martinez-Medina M., Garcia-Gil L.J. (2014). Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. World J. Gastrointest. Pathophysiol. 5, 213-227.
55. Marzorati M., Wittebolle L., Boon N., Daffonchio D., Verstraete W. (2008). How to get more out of molecular fingerprints: practical tools for microbial ecology. Environ. Microbiol. 10, 1571-1581.
56. McFarland L.V. (2008). Antibiotic-Associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 3, 563-578.
57. Meyer-Hoffert U., Hornef M.W., Henriques-Normark B., Axelsson L.G., Midtvedt T., et al. (2008). Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut. 57, 764-771.
58. Minot S., Bryson A., Chehoud C., Wu G.D., Lewis J.D., Bushman F.D. (2013). Rapid evolution of the human gut virome. Proc. Natl. Acad. Sci. USA. 110, 12450-12455.
59. Miquel S., Mart R., Rossi O., Bermez-Humar L.G., Chatel J.M., Sokol H., et al. (2013). Faecalibacterium prausnitzii and human intestinal health. Current Opinion in Microbiology. 16, 255-261.
60. Montalto M., DOnofrio F., Gallo A., Cazzato A., Gasbarrini G. (2009). Intestinal microbiota and its functions. Digestive and Liver Disease. (Suppl. 3), 30-34.
61. Musher D.M., Aslam S., Logan N., Nallacheru S., Bhaila I., Borchert F., Hamill R.J. (2005). Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40, 1586-1590.
62. Neemann K., Eichele D.D., Smith P.W., Bociek R., Akhtari M., Freifeld A. (2012). Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl. Infect. Dis. 14, E161-165.
63. Neish A.S. (2009). Microbes in gastrointestinal health and disease. Gastroenterology. 1, 65-80.
64. Nicholson J.K., Holmes E., Wilson I.D. (2005). Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 3, 431-438.
65. Nobuyuki Sudo, Yoichi Chida, Yuji Aiba, Junko Sonoda, Naomi Oyama, Xiao-Nian Yu, Chiharu Kubo, and Yasuhiro Koga. (2004). Postnatal microbial colonization programs the hypothalamic-pituitary-Adrenal system for stress response in mice. J. Physiol. 558, 263-275.
66. Ostaff M.J., Stange E.F., Wehkamp J. (2013). Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol. Med. 5, 1465-1483.
67. Parekh P.J., Balart L.A., Johnson D.A. (2015). The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. Clin. Transl. Gastroenterol. 18; 6:e91.
68. Pin J., Routhier S., Gagnon S., Brazeau I. (2006). Management and outcomes of a first recurrence of Clostridium difficile associated disease in Quebec, Canada. Clin. Infect. Dis. 42, 758-764.
69. Posseiers S., Bolca S., Verstraete W., Heyerick A. (2011). The intestinal microbiome: A separate organ inside the body with the metabolic potential to influence the bioactivity of botanicals. Fitoterapia. 82, 53-66.
70. Rawls J.F., Mahowald M.A., Ley R.E., Gordon J.I. (2006). Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell. 127, 423-433.
71. Sanz Y., Nadal I., Schez E. (2007). Probiotics as drugs against human gastrointestinal infections. Recent Pat. Antiinfect. Drug Discov. 2, 148-156.
72. Sartor R.B. (2008). Microbial influences in inflammatory bowel diseases. Gastroenterology. 134, 577-594.
73. Schauber J., Svanholm C., Termen S., Iffland K., Menzel T., Scheppach W., et al. (2003). Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut. 52, 735-741.
74. Schippa S., Conte M.P., Borrelli O., Iebba V., Aleandri M., Seganti L., et al. (2009). Dominant genotypes in mucosa-Associated Escherichia coli strains from pediatric patients with inflammatory bowel disease. Inflamm. Bowel. Dis. 15, 661-672.
75. Schippa S., Iebba V., Barbato M., Di Nardo G., Totino V., Checchi M.P., et al. (2010). A distinctive microbial signature in celiac pediatric patients. BMC Microbiol. 10, 175.
76. Schippa S., Iebba V., Totino V., Santangelo F., Lepanto M., Alessandri C., et al. (2012). A potential role of Escherichia coli pathobionts in the pathogenesis of pediatric inflammatory bowel disease. Can. J. Microbiol. 58, 426-432.
77. Sekirov I., Finlay B.B. (2006). Human and microbe: united we stand. Nat. Med. 12, 736-737.
78. Sekirov I., Russell S.L., Antunes L.C., Finlay B.B. (2010). Gut Microbiota in Health and Disease. Physiological Reviews. 90, 859-904.
79. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermez-Humar L.G., Gratadoux J.J., et al. (2008). Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysisof Crohn disease patients. Proc. Natl. Acad. Sci. USA. 105, 16731-16736.
80. Sommer F., Bkhed F. (2013). The gut microbiota masters of host development and physiology. Nat. Rev. Microbiol. 11, 227-238.
81. Sonnenburg E.D., Sonnenburg J.L., Manchester J.K., Hansen E.E., Chiang H.C., Gordon J.C. (2006). A hybrid two-component system protein of a prominent human gut symbiont couples glycan sens ing in vivo to carbohydrate metabolism. Proc. Natl. Acad. Sci. USA. 23, 8834-8839.
82. Term S., Tollin M., Rodriguez E., Sveinsdtir S.H., Jannesson B., Cederlund A., et al. (2008). PU.1 and bacterial metabolites regulate the human gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells. Mol. Immunol. 45, 3947-3955.
83. Van Nood, E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415.
84. Walters B.A., Roberts R., Stafford R., Seneviratne E. (1983). Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut. 24, 206-212.
85. Winter S.E., Winter M.G., Xavier M.N., Thiennimitr P., Poon V., Keestra A.M., et al. (2013). Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science. 339, 708-711.
86. Wylie K.M., Weinstock G.M., Storch G.A. (2012). Emerging view of the human virome. Transl. Res. 160, 283-290.
87. Zhang Y.J., Li S., Gan R.Y., Zhou T., Xu D.P., Li H.B. (2015). Impacts of Gut Bacteria on Human Health and Diseases. Int. J. Mol. Sci. 16, 7493-7519.
88. Zoetendal E.G., Rajilic-Stojanovic M., de Vos W.M. (2008). High-Throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut. 57, 1605-1615.